Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 13/20 | 0.35 |
| ▸ | ATR | Q13535 | 7/20 | 0.35 |
| ▸ | MTOR | P42345 | 10/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20120485 | 0.91 | TDO2 (0.33) | GSK3BTDO2ATMATRMTOR | |
| SCHEMBL20120487 | 0.91 | TDO2 (0.33) | GSK3BTDO2ATMATRMTOR | |
| SCHEMBL29548120 | 0.91 | TDO2 (0.33) | GSK3BTDO2ATMATRMTOR | |
| SCHEMBL20129249 | 0.90 | GSK3B (0.31) | GSK3BTDO2ATMATRMTOR | |
| SCHEMBL20133169 | 0.88 | PIK3CD (0.37) | GSK3BTDO2ATMATRPIK3CA | |
| SCHEMBL27097879 | 0.87 | ATM (0.36) | ATMATRMTORPIK3CAKCNH2 | |
| SCHEMBL20129161 | 0.86 | FAAH (0.33) | GSK3BTDO2ATMATRMTOR | |
| SCHEMBL20129086 | 0.85 | CTSS (0.36) | ATMATR | |
| SCHEMBL29547511 | 0.83 | TDO2 (0.38) | GSK3BTDO2ATMATRMTOR | |
| SCHEMBL20129037 | 0.83 | TDO2 (0.38) | GSK3BTDO2ATMATRMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | GSK3B 94/4885TDO2 3503/4885ATM 711/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | GSK3B 227/4885TDO2 3395/4885ATM 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.